{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:10:14Z","timestamp":1756293014019,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Lenalidomide is an immunomodulatory agent that was approved for the treatment of a monoclonal bone marrow disorders, myelodysplastic syndrome del(5q)(MDS del(5q)), in 2005; the drug was subsequently also approved for the treatment of refractory multiple myeloma, a bone marrow malignancy of the B-lymphocyte lineage. The purpose of this study is to report a case of MDS del(5q) in a female patient, which was most likely secondary to the immunosuppressive drugs that the patient was taking for scleritis. After lenalidomide treatment, the patient's haematological symptoms rapidly resolved and she became transfusion independent, with normal haemoglobin levels. This medication also helped control her dependence on high doses of oral prednisolone. The patient continued to receive treatment with low-dose lenalidomide, and her scleritis has been in long-term remission for 3\u2005years. A larger prospective study can further define the role of lenalidomide in the management of scleritis.<\/jats:p>","DOI":"10.1136\/bcr-2013-009092","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T10:29:59Z","timestamp":1371551399000},"page":"bcr2013009092","source":"Crossref","is-referenced-by-count":0,"title":["Can lenalidomide play a role in the management of scleritis?"],"prefix":"10.1136","volume":"2013","author":[{"given":"Hassan A","family":"Al-Jafar","sequence":"first","affiliation":[{"name":"Department of Haematology, Amiri Hospital, Kuwait, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Abul","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Al Bahar Eye Center, Shuwaikh, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niranjan","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Al Bahar Eye Center, Shuwaikh, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Al-Awadhi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kuwait University, Jabriya, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,6,18]]},"reference":[{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.survophthal.2005.04.001","article-title":"Major review","volume":"2013","author":"Okhravi","year":"2005","journal-title":"Scleritis Surv Ophthalmol"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3341\/kjo.2010.24.6.331","article-title":"Clinical features, predisposing factors and treatment outcomes of scleritis in the Korean population","volume":"2013","author":"Ahn","year":"2010","journal-title":"Korean J Ophthalmol"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/bjo.2009.171744","article-title":"Clinical features and visual outcomes of Japanese patients with scleritis","volume":"2013","author":"Keino","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2011.07.043","article-title":"Scleritis therapy","volume":"2013","author":"Sainz de la Maza","year":"2012","journal-title":"Ophthalmology"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0974-620X.91271","article-title":"Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis","volume":"2013","author":"Bawazeer","year":"2011","journal-title":"Oman J Ophthalmol"},{"issue":"Suppl 2","key":"2025082703320735000_2013.jun18_1.bcr2013009092.6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.cco.0000410243.84074.dc","article-title":"Review of therapy for relapsed\/refractory multiple myeloma: focus on lenalidomide","volume":"2013","author":"Mariz","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14656566.2012.656091","article-title":"Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies","volume":"2013","author":"Vallet","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1159\/000345098","article-title":"Complete remission of del(5q) myelodysplastic syndrome after 7\u2005days of lenalidomide therapy gives an alert!","volume":"2013","author":"Al-Jafar","year":"2012","journal-title":"Case Rep Oncol"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0161-6420(94)31325-X","article-title":"Severity of scleritis and episcleritis","volume":"2013","author":"Sainz de la Maza","year":"1994","journal-title":"Ophthalmology"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.60.3.163","article-title":"Scleritis and episcleritis","volume":"2013","author":"Watson","year":"1976","journal-title":"Br J Ophthalmol"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","article-title":"Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis","volume":"2013","author":"Murphy","year":"2004","journal-title":"Ophthalmology"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/asheducation-2011.1.556","article-title":"Immunomodulating drugs in myelodysplastic syndromes","volume":"2013","author":"Ad\u00e8s","year":"2011","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.13","doi-asserted-by":"crossref","unstructured":"Martiniani R Di Loreto V Di Sano C . Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol 2012;2012:842945.","DOI":"10.1155\/2012\/842945"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.exphem.2012.06.004","article-title":"Impact of lenalidomide on the functional properties of human mesenchymal stromal cells","volume":"2013","author":"Wobus","year":"2012","journal-title":"Exp Hematol"},{"key":"2025082703320735000_2013.jun18_1.bcr2013009092.15","doi-asserted-by":"crossref","unstructured":"McDaniel JM Pinilla-Ibarz J Epling-Burnette PK . Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012;2012:513702.","DOI":"10.1155\/2012\/513702"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-009092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:32:14Z","timestamp":1756290734000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-009092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,18]]},"references-count":15,"alternative-id":["10.1136\/bcr-2013-009092"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-009092","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2013,6,18]]}}}